Skip to main content


Placeholder slot

This page contains brief information about ipilimumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Ipilimumab is approved to treat:

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that ipilimumab provides a clinical benefit in these patients.

Ipilimumab is also being studied in the treatment of other types of cancer.

More About Ipilimumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Ipilimumab - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma

Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer

Targeted Cancer Therapies

Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors

Deaths from Metastatic Melanoma Drop Substantially in the United States

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Ipilimumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: